Company profilePharmaceutical#722 of 1,318 in Pakistan✓ No DRAP alerts

ASTER LIFE SCIENCES

Pharmaceutical company · 13 brands · 8 molecules

Ranked #14 of 15 companies in Immunosuppressants

13 registered products 14 pharmaceutical brands 8 distinct molecules 0 DRAP alerts

Company overview

13
registered products
14
pharmaceutical brands
8
distinct molecules
1
therapeutic classes
0
DRAP alerts

ASTER LIFE SCIENCES is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 13 product registrations across 8 distinct molecules. Its portfolio is concentrated in Immunosuppressants. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by ASTER

3 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

2
ceilings with an approval date
0
not revised in 2+ years
2026
oldest approval year
20262

Top molecules by brand count

Cyclosporin3 brands
Tacrolimus2 brands
Diphtheria Toxoid ...... 15 Lf2 brands
Paclitaxel1 brand
Octreotide1 brand

Therapeutic classes

Immunosuppressants · 1

Conditions treated

Auto Immune Disease · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official12 products · Rs 2,240.47 – Rs 41,334.31
Servaid1 products · Rs 6,152 – Rs 6,152
Median across source: Rs 12,632.17

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

Novartis Pharmaceuticals (Pvt) Ltd. holds 73 molecules not in this portfolio
AceclofenacAmlodipineAzithromycinBenzalkoniumBrinzolamideCaffeine
ALLMED LABORATORIES holds 60 molecules not in this portfolio
AlbuterolArtemetherArtesunateAscorbic AcidAzithromycinCalcium
BIOCARE PHARMACEUTICAL holds 10 molecules not in this portfolio
AzithromycinCefoperazoneColistimethate SodiumColistinFluconazoleInterferon Alfa-2B

Get the full profile for ASTER

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.